These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 24591996)
21. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220 [TBL] [Abstract][Full Text] [Related]
22. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test. Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581 [TBL] [Abstract][Full Text] [Related]
23. First-trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone. Sepulveda W; Wong AE; Dezerega V Obstet Gynecol; 2007 May; 109(5):1040-5. PubMed ID: 17470580 [TBL] [Abstract][Full Text] [Related]
24. [Diagnostic methods for fetal malformations in the first half of pregnancy]. Sieroszewski P; Suzin J; Baś-Budecka E Ginekol Pol; 2003 Oct; 74(10):1276-83. PubMed ID: 14669430 [TBL] [Abstract][Full Text] [Related]
26. Second-trimester prenatal screening for trisomy 21 using biochemical markers: a 7-year experience in one cytogenetic laboratory. Marical H; Douet-Guilbert N; Bages K; Collet M; Le Bris MJ; Morel F; De Braekeleer M Prenat Diagn; 2006 Apr; 26(4):308-12. PubMed ID: 16491510 [TBL] [Abstract][Full Text] [Related]
27. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700 [TBL] [Abstract][Full Text] [Related]
28. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186 [TBL] [Abstract][Full Text] [Related]
29. Diagnosis and management of fetal nuchal translucency. Jackson M; Rose NC Semin Roentgenol; 1998 Oct; 33(4):333-8. PubMed ID: 9800243 [TBL] [Abstract][Full Text] [Related]
30. Nuchal translucency thresholds in prenatal screening for Down syndrome and trisomy 18. Miron P; Côté YP; Lambert J J Obstet Gynaecol Can; 2009 Mar; 31(3):227-235. PubMed ID: 19416569 [TBL] [Abstract][Full Text] [Related]
31. Adenosine deaminase activity in subjects with normal pregnancy, pregnancy induced hypertension and pre-eclampsia. Oladipo OO; Afolabi BB; Okorodudu AO West Afr J Med; 2009 May; 28(3):161-4. PubMed ID: 20306731 [TBL] [Abstract][Full Text] [Related]
32. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Brizot ML; Snijders RJ; Butler J; Bersinger NA; Nicolaides KH Br J Obstet Gynaecol; 1995 Feb; 102(2):127-32. PubMed ID: 7538782 [TBL] [Abstract][Full Text] [Related]
33. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509 [TBL] [Abstract][Full Text] [Related]
35. A 1st-trimester combined screening test in pregnant women of advanced maternal age in a Chinese population. Pan M; Han J; Yang X; Zhen L; Liao C; Li DZ J Obstet Gynaecol; 2015 Feb; 35(2):121-4. PubMed ID: 25057869 [TBL] [Abstract][Full Text] [Related]
36. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Nicolaides KH Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343 [TBL] [Abstract][Full Text] [Related]
37. [Analysis of prenatal follow-up strategies for trisomy 21 affected pregnancies in France]. Dupont JM; Simon-Bouy B; Zebina A; Pessione F; Royère D; Doco-Fenzy M; Gynecol Obstet Fertil Senol; 2017 Mar; 45(3):152-157. PubMed ID: 28258854 [TBL] [Abstract][Full Text] [Related]
39. Screening for trisomy 21: the significance of a positive second trimester serum screen in women screen negative after a nuchal translucency scan. Sau A; Langford K; Auld B; Maxwell D J Obstet Gynaecol; 2001 Mar; 21(2):145-8. PubMed ID: 12521883 [TBL] [Abstract][Full Text] [Related]
40. Serum adenosine deaminase activity in women with pre-eclampsia. Yoneyama Y; Sawa R; Suzuki S; Otsubo Y; Miura A; Kuwabara Y; Ishino H; Kiyokawa Y; Doi D; Yoneyama K; Kobayashi H; Araki T Gynecol Obstet Invest; 2002; 54(3):164-7. PubMed ID: 12571439 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]